Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 242

1.

2,3,4,5-Tetrahydro-1H-pyrido[2,3-b and e][1,4]diazepines as inhibitors of the bacterial enoyl ACP reductase, FabI.

Ramnauth J, Surman MD, Sampson PB, Forrest B, Wilson J, Freeman E, Manning DD, Martin F, Toro A, Domagala M, Awrey DE, Bardouniotis E, Kaplan N, Berman J, Pauls HW.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5359-62. doi: 10.1016/j.bmcl.2009.07.094. Epub 2009 Jul 23.

PMID:
19682900
2.

Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI).

Sampson PB, Picard C, Handerson S, McGrath TE, Domagala M, Leeson A, Romanov V, Awrey DE, Thambipillai D, Bardouniotis E, Kaplan N, Berman JM, Pauls HW.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5355-8. doi: 10.1016/j.bmcl.2009.07.129. Epub 2009 Aug 6.

PMID:
19682901
3.

4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI.

Kitagawa H, Kumura K, Takahata S, Iida M, Atsumi K.

Bioorg Med Chem. 2007 Jan 15;15(2):1106-16. Epub 2006 Oct 13.

PMID:
17095231
4.

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).

Miller WH, Seefeld MA, Newlander KA, Uzinskas IN, Burgess WJ, Heerding DA, Yuan CC, Head MS, Payne DJ, Rittenhouse SF, Moore TD, Pearson SC, Berry V, DeWolf WE Jr, Keller PM, Polizzi BJ, Qiu X, Janson CA, Huffman WF.

J Med Chem. 2002 Jul 18;45(15):3246-56.

PMID:
12109908
5.

1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).

Heerding DA, Chan G, DeWolf WE, Fosberry AP, Janson CA, Jaworski DD, McManus E, Miller WH, Moore TD, Payne DJ, Qiu X, Rittenhouse SF, Slater-Radosti C, Smith W, Takata DT, Vaidya KS, Yuan CC, Huffman WF.

Bioorg Med Chem Lett. 2001 Aug 20;11(16):2061-5.

PMID:
11514139
6.

Novel enoyl-ACP reductase (FabI) potential inhibitors of Escherichia coli from Chinese medicine monomers.

Yao J, Zhang Q, Min J, He J, Yu Z.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):56-9. doi: 10.1016/j.bmcl.2009.11.042. Epub 2009 Nov 14.

PMID:
19959361
7.

In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis.

Karlowsky JA, Laing NM, Baudry T, Kaplan N, Vaughan D, Hoban DJ, Zhanel GG.

Antimicrob Agents Chemother. 2007 Apr;51(4):1580-1. Epub 2007 Jan 12. No abstract available.

8.

Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.

Seefeld MA, Miller WH, Newlander KA, Burgess WJ, Payne DJ, Rittenhouse SF, Moore TD, DeWolf WE Jr, Keller PM, Qiu X, Janson CA, Vaidya K, Fosberry AP, Smyth MG, Jaworski DD, Slater-Radosti C, Huffman WF.

Bioorg Med Chem Lett. 2001 Sep 3;11(17):2241-4.

PMID:
11527706
9.

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.

Seefeld MA, Miller WH, Newlander KA, Burgess WJ, DeWolf WE Jr, Elkins PA, Head MS, Jakas DR, Janson CA, Keller PM, Manley PJ, Moore TD, Payne DJ, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Uzinskas IN, Wallis NG, Huffman WF.

J Med Chem. 2003 Apr 24;46(9):1627-35.

PMID:
12699381
10.

Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus.

Takahata S, Iida M, Yoshida T, Kumura K, Kitagawa H, Hoshiko S.

J Antibiot (Tokyo). 2007 Feb;60(2):123-8.

PMID:
17420562
11.

Vibrio cholerae FabV defines a new class of enoyl-acyl carrier protein reductase.

Massengo-Tiassé RP, Cronan JE.

J Biol Chem. 2008 Jan 18;283(3):1308-16. Epub 2007 Nov 21.

12.

Aquastatin A, a new inhibitor of enoyl-acyl carrier protein reductase from Sporothrix sp. FN611.

Kwon YJ, Fang Y, Xu GH, Kim WG.

Biol Pharm Bull. 2009 Dec;32(12):2061-4.

13.

Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK.

Kitagawa H, Ozawa T, Takahata S, Iida M, Saito J, Yamada M.

J Med Chem. 2007 Sep 20;50(19):4710-20. Epub 2007 Aug 22.

PMID:
17713898
14.
15.

Vinaxanthone, a new FabI inhibitor from Penicillium sp.

Zheng CJ, Sohn MJ, Kim WG.

J Antimicrob Chemother. 2009 May;63(5):949-53. doi: 10.1093/jac/dkp058. Epub 2009 Mar 12.

PMID:
19282328
16.

CG400462, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor.

Park HS, Yoon YM, Jung SJ, Yun IN, Kim CM, Kim JM, Kwak JH.

Int J Antimicrob Agents. 2007 Nov;30(5):446-51. Epub 2007 Aug 27.

PMID:
17723291
17.

Cephalochromin, a FabI-directed antibacterial of microbial origin.

Zheng CJ, Sohn MJ, Lee S, Hong YS, Kwak JH, Kim WG.

Biochem Biophys Res Commun. 2007 Nov 3;362(4):1107-12. Epub 2007 Aug 31.

PMID:
17825252
18.

Discovery of a novel and potent class of FabI-directed antibacterial agents.

Payne DJ, Miller WH, Berry V, Brosky J, Burgess WJ, Chen E, DeWolf Jr WE Jr, Fosberry AP, Greenwood R, Head MS, Heerding DA, Janson CA, Jaworski DD, Keller PM, Manley PJ, Moore TD, Newlander KA, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Slater-Radosti C, Salyers KL, Seefeld MA, Smyth MG, Takata DT, Uzinskas IN, Vaidya K, Wallis NG, Winram SB, Yuan CC, Huffman WF.

Antimicrob Agents Chemother. 2002 Oct;46(10):3118-24.

19.

Structural insights into Staphylococcus aureus enoyl-ACP reductase (FabI), in complex with NADP and triclosan.

Priyadarshi A, Kim EE, Hwang KY.

Proteins. 2010 Feb 1;78(2):480-6. doi: 10.1002/prot.22581. No abstract available.

PMID:
19768684
20.

Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.

Lu H, Tonge PJ.

Acc Chem Res. 2008 Jan;41(1):11-20. doi: 10.1021/ar700156e. Review.

PMID:
18193820

Supplemental Content

Support Center